PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) this week reported its third quarter financial results for 2024, ...

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Passage Bio (PASG – Research Report) yesterday and set a price target ...

Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort ...

PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced that Will Chou, M.D., the president and chief executive officer ...

Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved ...

Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and ...

Neurology-Focused Passage Bio Reveals Initial Data From Dementia Study, Outlines Strategic Priorities Passage Bio Inc (NASDAQ: PASG) announced initial safety and biomarker data from three Cohort ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Traders use this information to analyze potential trades and assess market sentiment for Passage Bio. In The Money Expiration Date November 15, 2024 December 20, 2024 March 21, 2025 June 20, 2025 ...

PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.